- Home
- CCCS vs LEGN Comparison
CCCS vs LEGN Comparison
Compare CCCS & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCCS
- LEGN
- Stock Information
- Founded
- CCCS 1980
- LEGN 2014
- Country
- CCCS United States
- LEGN United States
- Employees
- CCCS N/A
- LEGN N/A
- Industry
- CCCS Computer Software: Prepackaged Software
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- CCCS Technology
- LEGN Health Care
- Exchange
- CCCS Nasdaq
- LEGN Nasdaq
- Market Cap
- CCCS 5.8B
- LEGN 5.4B
- IPO Year
- CCCS N/A
- LEGN 2020
- Fundamental
- Price
- CCCS $9.44
- LEGN $39.59
- Analyst Decision
- CCCS Buy
- LEGN Strong Buy
- Analyst Count
- CCCS 7
- LEGN 12
- Target Price
- CCCS $12.14
- LEGN $73.91
- AVG Volume (30 Days)
- CCCS 7.4M
- LEGN 1.5M
- Earning Date
- CCCS 07-31-2025
- LEGN 08-08-2025
- Dividend Yield
- CCCS N/A
- LEGN N/A
- EPS Growth
- CCCS N/A
- LEGN N/A
- EPS
- CCCS 0.01
- LEGN N/A
- Revenue
- CCCS $969,128,000.00
- LEGN $728,303,000.00
- Revenue This Year
- CCCS $13.36
- LEGN $65.33
- Revenue Next Year
- CCCS $9.24
- LEGN $54.68
- P/E Ratio
- CCCS $741.79
- LEGN N/A
- Revenue Growth
- CCCS 9.05
- LEGN 112.46
- 52 Week Low
- CCCS $8.14
- LEGN $27.34
- 52 Week High
- CCCS $12.88
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- CCCS 52.18
- LEGN 68.12
- Support Level
- CCCS $9.17
- LEGN $38.86
- Resistance Level
- CCCS $9.85
- LEGN $40.78
- Average True Range (ATR)
- CCCS 0.25
- LEGN 1.52
- MACD
- CCCS -0.01
- LEGN 0.33
- Stochastic Oscillator
- CCCS 43.36
- LEGN 85.77
About CCCS CCC Intelligent Solutions Holdings Inc.
CCC Intelligent Solutions Holdings Inc is a provider of cloud, mobile, AI, telematics, hyperscale technologies and applications for the property and casualty insurance economy. The company's SaaS platform connects trading partners, facilitates commerce, and supports mission-critical, and AI-enabled digital workflows. It operates in a single segment being Domestic segment which provides SAAS platform for the P&C insurance economy and derives revenues from providing customers with software subscriptions to the platform in addition to providing professional services and non-software services. The company has its presence in United States and China. Majority of the revenue is generated from United States.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.